eBook: The role of RWE in regulatory approvals. Download here.

FDA Decision Alerts June 24, 2021

CDER-Approved NDA for LAMPIT® (nifurtimox)

Nick Honig and Michelle Skornicki
Contributing writers, Aetion

On August 6, 2020, FDA granted accelerated approval to Bayer Healthcare’s LAMPIT® (nifurtimox) “for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi.” Of note: Bayer Healthcare received Orphan designation and a tropical disease priority review voucher.

Key findings from the FDA’s Multidiscipline Review:

The applicant provided substantial evidence of effectiveness through Study 16027 (NCT02625974; n=330), a phase 3, randomized, double-blind clinical trial with a historical control arm.

Intent of the historical control
When designing Study 16027, the applicant used a surrogate endpoint to measure effectiveness: change in serologic results or a 20% decrease in optical density. The applicant intended to compare the treatment group to a historical control, using the surrogate endpoint.

Protocols for historical control generation
The applicant created a historical control using two published randomized controlled trials: Sosa Estani (1998) and De Andrade (1996). The applicant determined a 16% placebo control rate would be appropriate, given the published studies.

Outcome of the historical control submissions
FDA concluded that there were limited data supporting the applicant’s selection of a 16% placebo control rate. FDA therefore based its efficacy assessment on a comparison of the randomized treatment arms, instead of the historical control. FDA used the historical control in its assessment of the exploratory endpoint of F29 ELISA serological testing, a “non-conventional” form of serological testing. The reviewer concluded that the historical control provided evidence of effectiveness in the secondary endpoint.

RWE included in the application
FDA also provided a prospective and retrospective cohort study, Fabbro (2007), to support the finding that seroconversion to negative is linked to a lower risk of cardiac abnormalities.

The applicant provided post-marketing data to support nifurtimox’s safety profile. For its review of safety, FDA noted that the postmarketing data show a risk of hypersensitivity and skin reactions, as well as thrombocytopenia, which are cited in the label. The label also mentions that postmarketing data do not show a link between nifurtimox and birth defects.

FDA Decision Alerts

Subscribe to our FDA Decision Alerts for emails as we add new summaries of RWE used in FDA decisions to our library.

eBook

The role of real-world evidence in FDA approvals

View now
arrowcalendarchevronclosecollapsecountdownfacebookflickrinstagramlinelinkedinlocationpinsearchsocialtwitteryoutube